Epicyt Pharma AB has reported positive topline results from its Phase 1/2a first-in-human study evaluating BAFA in patients who had undergone Roux-en-Y Gastric Bypass (RYGB) surgery.

The study demonstrated a statistically significant reduction in urinary calcium excretion, along with improvements in key biomarkers associated with calcium homeostasis. According to the company, the findings are consistent with improved intestinal calcium uptake and support the advancement of BAFA into Phase 2b development.

BAFA is an oral drug candidate designed to enhance intestinal calcium absorption by combining a bile acid with a short-chain fatty acid. The Phase 1/2a study was completed in March 2026.

RYGB is widely used to treat severe obesity but can impair intestinal calcium absorption. This may contribute to secondary hyperparathyroidism, reduced bone density and an increased risk of fractures. Current management generally relies on calcium and vitamin D supplementation, highlighting the need for therapies that can directly improve calcium absorption and maintain calcium balance following bariatric surgery.

Epicyt Pharma estimates that approximately 3.5 million people in the EU and US have impaired calcium homeostasis following gastric surgery for obesity, with around 250,000 new patients affected each year.

Based on the Phase 1/2a findings, the company is preparing to progress BAFA into Phase 2b clinical development.